Clinical Trial Update: Extension Study of Infigratinib in Children With Achondroplasia (ACH) [Phase 2]

View source ↗

Summary

An extension study of Infigratinib for children with achondroplasia is in Phase 2 and currently enrolling by invitation. The study is sponsored by QED Therapeut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Achondroplasia | Phase 2 | Status: ENROLLING_BY_INVITATION